C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain anemic. Pegcetacoplan (APL‐2), a PEGylated C3 inhibitor,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology Jg. 95; H. 11; S. 1334 - 1343
Hauptverfasser: Castro, Carlos, Grossi, Federico, Weitz, Ilene Ceil, Maciejewski, Jaroslaw, Sharma, Vivek, Roman, Eloy, Brodsky, Robert A., Tan, Lisa, Di Casoli, Carl, El Mehdi, Delphine, Deschatelets, Pascal, Francois, Cedric
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Hoboken, USA John Wiley & Sons, Inc 01.11.2020
Wiley Subscription Services, Inc
Schlagworte:
ISSN:0361-8609, 1096-8652, 1096-8652
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!